FDA Approval
NEWS RELEASE
U.S. Food and Drug Administration Approves Gilead’s Single Tablet Regimen Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection
(November 05, 2015)
ARV
Main Page
Main New/Newsworthy
Home Page
E
lvitegravir 150 mg (E), Cobicistat 150 mg (C), Emtricitabine 200 mg (F),
and Tenofovir Alafenamide 10 mg
(E/C/F/TAF) (Genvoya®)
ARV
Main Page
Main
New/Newsworthy